$PTN Longshot? or not?

Drug for female sexual dysfunction (FSD). Bremelanotide is an on-demand melanocortin receptor agonist that acts in the central nervous system to positively impact sexual response. The treatment is being developed for the large FSD indication that includes up to 20% of women in the US, but for which there is no FDA-approved drug treatment.
"Palatin's bremelanotide has a history of positive clinical trial data and a mechanism of action that directly impacts sexual response," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "The lack of competition in the FSD market coupled with a near-term Phase III trial gives Palatin an edge as bremelanotide moves closer to market."

Full Pipeline products with colaboration from AstraZeneca. See website......
Bremelanotide, a peptide melanocortin receptor agonist, for treatment of FSD. This drug candidate has completed a Phase 2B clinical trial, and we have announced top-line results.
Melanocortin receptor-based compounds for treatment of obesity, under development by AstraZeneca AB (AstraZeneca) pursuant to our research collaboration and license agreement.
PL-3994, a peptide mimetic natriuretic peptide receptor A (NPR-A) agonist, for treatment of cardiovascular and pulmonary indications.